1Arkfeld DG. The potential utility of B cell-directed bioloyic therapy in autoimmune diseases [J]. Rheumatol lnt, 2008, 28 (3):205-215.
2Vallerskog T, Heimburge M, Gunnarsson I, et al. Differential effects on BAFF and APRIl. levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis[J]. Arthritis Res Ther,2006,8(6) :R167.
3Tokunaga M,Saito K, Kawabata D, et al. Efficacy of rituximab ( anti-CD20 ) for refractory systemic lupus erythematosus involving the central nervous system[J]. Ann Rheum Dis,2007, 66(4): 470-475.
4Pitashny M, Shoenfeld Y. B cell depletion in autoimmune rheumatic diseases[J]. Autoimmun Rev, 2005,4 (7) : 436-441.
5Zaja F, Battista MI., pirrotta MT, et al. Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura[J]. Haematologica, 2008,93(6) : 930- 933.
6Zheng WJ, Zhang X, Wang Q, et ah Refractory severe connective tissue disease thrombocytopenia:is rituximab treatment effective and salt? [J].Ann Rheum Dis,2009,68(6):1077-1078.
7Isenberg DA. B cell targeted therapies in autoimmune diseases [J]. Rheumatol, 2006,77 (Suppl) : 24.
8Vigna Perez M, Hernandez-Castro B, Paredes Saharopulos O, et al. Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to convetional therapy: a pilot study[J]. Arthritis Reseach & Therapy,2006,8(3):R83.
9Anolik JH, Barnard J, Cappione A, et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus[J]. Arthritis Rheum, 2004,50 ( 11 ) : 3580-3590.
4Bosch X, Guilabert A, Espinosa G, et al. Treatment of antineu- trophil cytoplasmic antibody associated vasculitis., asystematic reviewC.J]. JAMA, 2007,298(6) : 655-669.
5Gorman C, Leandro M, Isenberg D. B cell depletion in autoimmune disease [J]. Arthritis Res Ther, 2003, 15 (Suppl 4): 17-21.
6Vallerskog T , Heimburge M , Gunnarsson I, etal. Dif- ferential effects on BAFF and APRIL levels in rituximab- treated patients with systemic lupus erythematosus and rheumatoid arthritis [J]. Arthritis Res Ther, 2006, 8 ( 6) : 167.
7Edwards JC, Cambridge G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. [J]. Nat Rev Immunol, 2006,6(5) :394-403.
8Reynolds JA, Toescu V, Yee CS. Effects of rituximab on resistant SLE disease including lung involvement[J]. Lupus,2009,18(1 ) :67 -73.
9Looney RJ, Anolik JH, Campbell D, etal . B cell deple tion as a novel treatment for systemic lupus erythemato sus: a phase I/II dose-escalation trial of rituximab[J] Arthritis Rheum, 2004,50 (8) : 2580-2589.
10Sfikakis PP, Boletis JN, Lionaki S, et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell cos- timulatory molecule CD40 ligand: an open label trial[J]. Arthritis Rheum, 2005,52 (2) : 501-513.
